Opportunities in China

Are you interested in exploring potential possibilities in China market? Currently we are actively helping our Chinese clients seek strategic partners. Contact us if your product falls into one of these categories:

  • Drugs under 505(b)(2) pathway, and hold high competition barrier.
  • Drugs or medical device in psychiatry areas, including but not limited to depression, Schizophrenia, bipolar disorder, and anxiety.

Participating Companies

We are going to bring together 100+ Chinese pharma and medical device companies and investors at China Focus@BIO Philadelphia, you can schedule 1-to-1 meetings with attendees from following companies after registration. Early bird rate is available until April 28th.

Register Now&Save $150

 

Highlights of Private Pitch Session

 

The private pitch is an invitation only session. The audiences are high profile pharma executives and investors, exclusively. All the presenting companies are selected based on their key credentials, potential for Chinese market, and the feedback from the audiences. Click here to learn more.

 

»  Exclusive Audiences
(Previous Audience List)
»  Selected Presenting Companies
»  Unique Format

»  Private and Focused

»  Immediate Follow-Up Meetings
»  On-Target Partnering

Apply to Pitch

 

Innovation Competition

MyBioGate Global Healthcare Innovation Competition is still accepting applications! Click here to learn more about preliminary schedule and featured prizes.

Companies selected from online applications will get:

  • The opportunity for media coverage and promotion on our English and Chinese platforms.
  • 1-to-1 partnering opportunities with potential Chinese investors.
  • Exhibition space for your company at China Focus forum with a surprise discount.
  • The opportunity for a 5-day sponsored business development trip in China to meet 100+ investors and corporate executives.                                                                         Upcoming Preliminaries: 
  • April 30, Online(zoom webinar)
  • Time: April 30, 10:00 AM (GMT +8, Beijing, Shanghai)
  • Register in advance for this webinar: https://zoom.us/webinar/register/801dc1c3a3a17d4adc2040ba88984b7b
  • June 2, Philadelphia
Submit Application

 

Cross-border Investment News

Shanghai Miracogen taps Synaffix’s antibody-drug conjugate tech in a deal worth up to $125M
Cancer-focused Shanghai Miracogen is looking to boost its pipeline by adding Synaffix’s tools for building antibody-drug conjugates to its arsenal. In a deal that could be worth $125 million, Miracogen is licensing two platforms to bring its next candidate into the clinic.